Srsf2^P95H/+ cells are sensitive to the CDK6 inhibitor palbociclib and the spliceosome inhibitor Pladienolide B. (A) The guide count for CDK6 sgRNA in Srsf2^+/+ and Srsf2^P95H/+ cells over the course of the screen. (B) The cell-cycle stage distribution of Srsf2^P95H/+ and Srsf2^+/+ cells at day 18 after tamoxifen cessation. No statistical difference detected between P95H and WT cells. (C) Hoxb8 GM-CSF Srsf2^P95H/+ cell lines and sorted primary Srsf2^P95H/+ LKS⁺ cells are sensitive to palbociclib and Pladienolide B after 4 days of drug culture. Hoxb8 GM-CSF cell lines: n = 3 per genotype for roscovitine and Pladienolide B, n = 2 for palbociclib. Extra sum-of-squares F test. LKS⁺ cells, n = 1 per genotype. LKS⁺, lin⁻ckit⁺Sca-1⁺.